JUPITER NEUROSCIENCES, INC. JUNS
other sections of this Annual Report on Form 10-K, includes statistical and other industry and market data that we obtained from industry
publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and
studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee
the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $21.8K | $0 | — | — |
| Cost of revenue | $4.2K | — | — | — |
| Gross profit | $17.6K | — | — | — |
| R&D | $2.1M | $492.7K | $954.8K | — |
| SG&A | $6.8M | $2.6M | $2.9M | — |
| Total operating expenses | $8.9M | $3.1M | $3.9M | — |
| Operating income | -$8.9M | -$3.1M | -$3.9M | — |
| Interest expense | $66.0K | $248.4K | $218.7K | — |
| Net income | -$8.6M | -$2.4M | -$4.8M | — |
| EPS, basic | -0.25 | -0.08 | -0.18 | — |
| EPS, diluted | -0.25 | -0.08 | -0.18 | — |
| Shares, diluted (wtd. avg.) | $34.6M | $28.8M | $26.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Receivables | $2.6K | — | — | — |
| Inventory | $159.8K | — | — | — |
| Total current assets | $4.8M | $4.7M | $28.7K | — |
| Total assets | $5.6M | $6.2M | $148.6K | — |
| Accounts payable | $638.6K | $396.5K | $546.0K | — |
| Total current liabilities | $7.4M | $2.0M | $5.8M | — |
| Total liabilities | $7.4M | $2.0M | $5.9M | — |
| Retained earnings | -$34.7M | -$26.0M | -$23.6M | — |
| Total equity | -$1.8M | $4.2M | -$5.8M | -$7.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$5.4M | -$3.9M | -$481.0K | — |
| Stock-based compensation | $2.4M | $1.8M | $50.0K | — |
| Financing cash flow | $5.4M | $7.7M | $445.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014687.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |